Lupus purple was seen throughout the Capitol this week when advocates representing the Lupus Research Alliance visited Congress to tell members why they must allocate more funds to lupus research. You can join long-distance – just reach out to your representatives and senators by email and phone using our Legislative Action Center! Our advocacy has […] READ MORE
WASHINGTON, DC – March 19. Lupus Research Alliance (LRA), the world’s largest private funder of lupus research, celebrates its 15th Annual Advocate for Lupus Research Day on Capitol Hill today, sounding the need for increased federal funding to further advance new lupus treatments and a cure. Advocates representing the Lupus Research Alliance are on the […] READ MORE
March 19, 2019 A new study published in Lupus showed that mycophenolate mofetil (MMF) is comparable in effectiveness to the standard treatment intravenous cyclophosphamide (IVCYC) for lupus nephritis in pediatric patients. The study compared response to treatment, kidney damage, time needed to result in inactive lupus nephritis and disease flares. Of the 51 patients studied, […] READ MORE
Thanks to the Lupus Research Alliance Team Life Without Lupus, with runners who pounded the pavements at the United Airlines NYC Half Marathon on Sunday to raise funds for lupus research. Every one of those 13.1 miles bring us closer in the journey to Life Without Lupus – their invaluable steps brought the Team’s fundraising […] READ MORE
A new study funded by the Lupus Nephritis Trials Network with support from the Lupus Research Alliance has proposed a set of standardized measures that promise to improve the way clinical trials in lupus nephritis (LN) are structured and how clinical researchers report their results. The findings will also help researchers in their search for […] READ MORE
A new study published in the peer-reviewed journal Lupus shows that lupus can cause damage to the peripheral nervous system (nerves throughout the body outside of the brain and spinal cord). Researchers from several hospitals in Italy analyzed medical records of 1224 lupus patients. Involvement of the peripheral nervous system was seen in 6.9% of […] READ MORE
NEW YORK, NY. March 14, 2019. The Lupus Research Alliance (LRA) and the National Minority Quality Forum (NMQF) today released the insightful report, Addressing the Challenges of Clinical Research Participation Among Populations Disproportionately Impacted by Lupus. The report presents findings and actionable recommendations ranging in scope that can be implemented by any individual or group seeking […] READ MORE
March 11, 2019 A new study published in Arthritis & Rheumatology by many top lupus clinicians found that a frailty index (FI) provides a novel measure of health among people with lupus. Constructed using data from the Systemic Lupus International Collaborating Clinics (SLICC) group, the FI also predicts risk of mortality. The Systemic Lupus Erythematosus […] READ MORE
NEW YORK, NY. March 6. Depleting the number of harmful B cells with a novel immunotherapy that employs modified T cells may offer an effective strategy to treat lupus, according to a new study funded by the Lupus Research Alliance. These findings offer a renewed optimism for the elimination of B cells to provide a […] READ MORE
New York, NY– March 1. The Lupus Research Alliance and its affiliate, Lupus Therapeutics announced a collaboration with Takeda Pharmaceutical Company Limited, to evaluate the investigational biologic TAK-079 as a potential new therapy for lupus in a Phase 1 trial (NCT03724916). The national study will be conducted in 20 research centers throughout the country, many […] READ MORE
February 28, 2019 NEW YORK, NY. As a co-sponsor of the National Institutes of Health (NIH) public-private Accelerating Medicines Partnership (AMP), the Lupus Research Alliance is proud to share the project’s five-year achievements reported in Nature Reviews Drug Discovery. In the article, NIH Director Dr. Francis Collins points to new technology standards AMP created for […] READ MORE
February 28, 2019 Proteins of the immune system, known as type I interferons, are responsible in part for manifestations of lupus. For this reason, type I interferons are a very attractive target for lupus drug development. In 2015, excitement surrounded the release of positive phase II data with anifrolumab, a therapeutic antibody that blocks type […] READ MORE
